These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 15654581

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
    Mirkin S, Komm BS, Pan K, Chines AA.
    Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
    [Abstract] [Full Text] [Related]

  • 6. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women.
    Utian WH, Gass ML, Pickar JH.
    Menopause; 2004 Jun; 11(3):306-14. PubMed ID: 15167310
    [Abstract] [Full Text] [Related]

  • 7. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
    Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G.
    Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
    [Abstract] [Full Text] [Related]

  • 10. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC, Fowler SE, Detter JR, Sherman SS.
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
    Gutteridge DH, Holzherr ML, Retallack RW, Price RI, Will RK, Dhaliwal SS, Faulkner DL, Stewart GO, Stuckey BG, Prince RL, Criddle RA, Drury PJ, Tran L, Bhagat CI, Kent GN, Jamrozik K.
    Calcif Tissue Int; 2003 Jul; 73(1):33-43. PubMed ID: 14506952
    [Abstract] [Full Text] [Related]

  • 13. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
    Arrenbrecht S, Boermans AJ.
    Osteoporos Int; 2002 Jul; 13(2):176-83. PubMed ID: 11908492
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
    Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.
    Ann Intern Med; 2002 Dec 03; 137(11):875-83. PubMed ID: 12458987
    [Abstract] [Full Text] [Related]

  • 16. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E.
    Osteoporos Int; 2004 May 03; 15(5):396-404. PubMed ID: 14676992
    [Abstract] [Full Text] [Related]

  • 17. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
    Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, Women's Health Initiative Investigators.
    JAMA; 2003 Oct 01; 290(13):1729-38. PubMed ID: 14519707
    [Abstract] [Full Text] [Related]

  • 18. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
    Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento-Villareal R, Yokoyama-Crothers N, Kardaris EE, Hauser J, Cohen S, Hildebolt CF.
    Arch Intern Med; 2002 Jun 24; 162(12):1409-15. PubMed ID: 12076241
    [Abstract] [Full Text] [Related]

  • 19. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal bone loss: a comparison of high- and low-dose estrogen-progestin regimens.
    Heikkinen J, Vaheri R, Kainulainen P, Timonen U.
    Osteoporos Int; 2000 Jun 24; 11(11):929-37. PubMed ID: 11193245
    [Abstract] [Full Text] [Related]

  • 20. Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.
    Yoon BK, Lee DY, Park MC, Cho SH, Park HM, Choi YM.
    J Korean Med Sci; 2017 Jun 24; 32(6):992-998. PubMed ID: 28480658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.